eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
4/2022
vol. 47
 
Share:
Send email
Share:
abstract:
Review paper

The emerging role of triggering receptor expressed on myeloid cell-2 in malignant tumor

Yahui Wang
1
,
Ying Chu
1
,
Fenghua Cao
2
,
Zhihong Chen
3
,
Huaxi Xu
1
,
Shengjun Wang
1
,
Jie Ma
1

  1. Department of Immunology, Department of Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China
  2. Zhenjiang Hospital of Traditional Chinese and Western Medicine, Zhenjiang, China
  3. Department of Gastrointestinal Surgery, Affiliated Renmin Hospital of Jiangsu University: Zhenjiang First People’s Hospital, Zhenjiang, Jiangsu, China
Cent Eur J Immunol 2022; 47 (4): 373-381
DOI: https://doi.org/10.5114/ceji.2022.124387
Online publish date: 2023/01/31
View full text Get citation
 
PlumX metrics:
Triggering receptor expressed on myeloid cell-2 (TRE M2) is a transmembrane receptor which is specifically expressed on myeloid cells. To date, TRE M2 has been confirmed as a key factor in many pathologies, such as Alzheimer’s disease, obesity-related metabolic syndrome, fatty liver and atherosclerosis. However, the role of TRE M2 in tumors remains poorly understood. TRE M2 is highly expressed in more than 200 primary and metastatic tumors, a feature that makes TRE M2 a potential clinical target for tumor immunotherapy. The tumor microenvironment (TME) is the “soil” which tumors survive on and exhibits immunosuppressive characteristics. During the development of a tumor, TME will secrete

various chemotactic factors to recruit myeloid cells. It is clear now that cancer progression and metastasis depend on the interactions between cancer cells and myeloid cell infiltration in TME. As an important receptor involved in inflammatory suppression signaling pathways, TRE M2 may play an important role in immune escape by the tumor. Recently, several studies have illustrated that TRE M2 expressed on tumor infiltrated myeloid cells acts as a crucial regulator of the antitumor immune response. In this review, we systematically summarize recent publications about the latest advances in knowledge of TRE M2 in cancer, especially focusing on its role in tumor associated myeloid cells and tumor immunotherapy.
keywords:

triggering receptor expressed on myeloid cell-2, malignant tumor, tumor immunotherapy, tumor infiltrating myeloid cells
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.